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Beneficial Effects of Simvastatin
and Pravastatin on Cardiac
Allograft Rejection and Survival
In their study comparing beneficial effects of simvastatin and
pravastatin on cardiac allograft rejection and survival, Mehra et al.
(1) concluded both statins to be equivalent and superior to
no-statin treatment. Clinical trials whose purpose are to show
equivalence/noninferiority of two or more treatments commonly
apply methods to demonstrate superiority and, if no statistical
differences are found, treatments are assumed to be equivalent. The
correct approach, however, would be to calculate sample sizes using
bio-equivalence formulae (2). Although the findings of the statin
trial are reassuring, the study could have been underpowered.
Could the investigators comment on power-size calculation prior
to this study and whether the concept of equivalence testing was
adhered to?
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REPLY
I am grateful to Dr. Conraads for the opportunity to respond to the
issues raised and am pleased to note that our findings provide
reassurance to our colleague in the comparative usefulness of either
simvastatin or pravastatin following cardiac transplantation. Ever
since the original publication by Kobashigawa et al. (1), wherein
the beneficial immunomodulating properties of pravastatin on
indices of cardiac allograft rejection were reported, it has remained
an enigma whether other drugs within the class share this property.
Assuming a 25% incidence of allograft rejection requiring treat-
ment at one year, given the cohort size, the current study had 80%
power to detect a 15% difference in rejection rates between either
pravastatin or simvastatin, with a type-1 error of 0.05. Thus, based
on our results, it is unlikely that pravastatin is superior to
simvastatin in abrogating cardiac allograft rejection.
Insofar as the issue of survival is concerned, we agree that the
study could have been underpowered as a single-center experience
is unlikely to enroll the requisite number of transplants that would
be required to confirm or refute a difference in survival alone.
Nevertheless, we must emphasize that the survival rates in our
study (92% and 91% for pravastatin and simvastatin, respectively)
are in agreement with those previously reported by other single-
center studies (95%) of statins (1) and superior to those reported by
multicenter registry databases (83%) that have a relatively low
penetration of statin use (2). Because allograft rejection is the
prime driver of survival in the first year, we strongly believe that
our study should restore confidence in the similar safety and
efficacy of low-dose statin therapy and steer us toward a more
universal use of these agents to enhance outcomes in cardiac
transplantation.
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